Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NP006
- Development stage
- Unknown
- Lead developer
- Shanghai Saierxin Biomedical Technology
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
NP006 is an autologous polyclonal regulatory T cell (Treg) therapy developed by Shanghai Saierxin Biomedical Technology (NovaBio). It is designed to treat autoimmune diseases by restoring immune tolerance through the suppression of aberrant immune responses. The therapy involves the isolation, ex vivo expansion, and subsequent intravenous re-infusion of a patient's own Treg cells. NP006 is currently being evaluated in investigator-initiated trials (IIT) for indications including autoimmune hepatitis (AIH) and Type 1 Diabetes (T1D), and is undergoing IND-enabling studies for formal clinical development.
- Other names
- Polyclonal Treg cell therapy
Beyond the preview
Go deeper on NP006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NP006.